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ABSTRACT 
Objective: Despite the fact that there was no adverse effect observed in previous animal safety studies of Deinococcus grandis (D. grandis) 
fermented soymilk, including acute oral toxicity assay, 3 different test systems of genotoxicity test and teratogenicity study, whether D. grandis 
fermented soymilk is safe for long-term use remains unknown. Therefore, the study was conducted further to clarify the edible safety of D. grandis 
fermented soymilk for long term use. 
Methods: Eighty Sprague-Dawley (SD) rats were divided into four groups, each consisting of ten male and ten female rats. Rats were orally 
administrated with reverse osmosis water (control) or 1,000, 2,000 and 3,000 mg/kg b.w./d freeze dried D. grandis fermented soymilk powder for 
90 consecutive days. Clinical observation of the rats was carried out daily. The body weight and feed intake of the rats were recorded weekly. At the 
end of the study, all rats were sacrificed and the blood and organs were collected for hematology, clinical biochemistry and histopathological 
examination. 
Results: During the study period, no abnormality occurred in clinical signs, body weight, and ophthalmological examination. There were no 
significant differences in urinalysis, hematology and clinical biochemistry parameters between the treatment and control group. Necropsy and 
histopathological examination showed no treatment-related change. 
Conclusion: According to the results, the no-observed-adverse-effect level (NOAEL) of D. grandis fermented soymilk was greater than 3,000 mg/kg 
b.w./d in SD rats. 
Keywords: Deinococcus grandis (D. grandis), 90-day subchronic toxicity, NOAEL, Safety assessment, GKB-Aid 1995 
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INTRODUCTION 
Soybean is an annual herb belonging to the family Leguminosae and 
the genus Glycine [1]. It has been cultivated in China for over 4,700 y 
[2]. Soybean exhibits a variety of beneficial biological effects on 
human health, such as cholesterol and triglycerides reduction [3, 4], 
improved vascular health [5], preserved bone mineral density [6], 
reduction of menopausal symptoms [7], anti-cancer effects [8], and 
immunomodulation [9]. There are many active ingredients of high 
nutritional value in soybeans, including isoflavones, saponins, phytic 
acid, phytosterols, phenolic acids and trypsin inhibitors [10-12]. In 
Asia, soybean is normally prepared as fermented products, such as 
soy sauce, natto, tempeh and fermented soybean curd, to improve 
digestibility and increase bioavailability [13]. Moreover, the 
fermented process of soybeans produces better flavor and health-
promoting substances [14].  
In 1995, we isolated a strain of aerobic, non-motile, non-spore-
forming, rod-shaped, orange-red, gram-negative bacteria exhibited 
antioxidant activity from the soil. Chemotaxonomic data showed 
that the predominant cellular fatty acid was C16:1ω7c (22.43%) and 
C15:1ω6c (17.96%), suggesting that the strain belongs to the genus 
Azomonas [15]. However, taxonomic classification by such method is 
objective because of phenotypic variations. With advanced isolation 
and identification, the 16S ribosomal RNA (rRNA) gene PCR analysis 
and Vitek 2 colorimetric GN card were developed to overcome this 
drawback. The 16S rRNA gene PCR analysis is the gold standard for 
specification of bacteria for which the gene is highly conserved 
among species of the same genus [16]. Vitek, 2 colorimetric GN card, 
is a promising tool to identify gram-negative rods fast and accurately 
[17]. The result of Vitek 2 GN card showed that the strain was 
characteristically similar to Deinococcus grandis (D. grandis) ATCC 
43672 (97.9%) [18]. The only difference from D. grandis is that the 
strain does not produce L-Pyrrolydonyl-Arylamidase [18]. Analysis 
of the 16S rRNA nucleotide sequences revealed that the strain has a 
high degree of sequence similarity (98.4%) with the D. grandis ATCC 
43672 strain [18]. Based on these results, the strain was identified 
as D. grandis [18] and named as GKB-Aid 1995. 
The Lab of Bioengineering Center of Grape King Bio Ltd obtained the 
fermented soymilk with high nutritional value by adding D. grandis 
to soymilk (Brix 4) to completely convert isoflavone glycosides into 
daidzin and genistin in 24 h [19]. D. grandis fermented soymilk 
increased the host immunity by inducing Th1 immune responses 
[19]. Our previous studies demonstrated that no toxic effect was 
observed in acute oral toxicity assay, 3 different test systems of 
genotoxicity test and teratogenicity study (submitted). Despite the 
fact that there is no adverse effect observed in previous animal 
safety studies, whether D. grandis fermented soymilk is safe for long-
term use remains unknown. In the present study, we conducted a 
90-day subchronic toxicological assessment of D. grandis fermented 
soymilk in Sprague-Dawley (SD) rats to confirm the edible safety 
and evaluate the no-observed-adverse-effect level (NOAEL) of D. 
grandis fermented soymilk. 
MATERIALS AND METHODS 
Preparation of D. grandis fermented soymilk  
For 90-day subchronic toxicological assessment, D. grandis cultured 
on trypsin soy agar was transferred to a 2 l Erlenmeyer flask with 1 l 
broth consisting of 2% sucrose, 1% peptone, 1% yeast extract, and 
soy milk. The whole medium was cultivated at 32 °C for 24 h on a 
rotary shaker (120 rpm) for seed culturing prior to its scale-up 
production step. The scale-up of the fermentation process was 
performed using the same media in the 20-ton fermenter agitated at 
60 rpm with an aeration rate of 0.5 vvm at 32 °C for 24 h. At the end 
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of the cultivation, 2 x 109 CFU/ml D. grandis in fermentation media 
was obtained and then heated at 60 °C. After lyophilized, 1.3 g freeze-
dried powder can be acquired from 1 l fermentation media. The freeze 
dried powder was then reduced to a fine dried powder using a 60 
mesh and stored in a desiccator at room temperature. [18] 
Animals 
Eighty 5-week-old SD rats were obtained from BioLASCO Taiwan 
Co., Ltd (Yilan, Taiwan). After quarantined and accommodation for 
one week, the rats were randomized based on their body weight and 
then entered the study. The rats had free access to standard rodent 
diet and sterile reverse osmosis water (R. O. water) ad libitum and 
were maintained at a controlled temperature (22±3℃), relative 
humidity (55±15%) and light cycle (12 h light/12 h dark). The 
frequency of ventilation was 10-15 time/h. 
Study design 
This study was performed based on the safety assessment guideline 
of Health Food announced by the Ministry of Health and Welfare 
(Taiwan). The protocol was approved by the Institutional Animal 
Care and Use Committee (IACUC No. 103-9j) before the beginning of 
the study. The rats were randomly divided into four groups 
(n=10/sex/group) and orally administrated with D. grandis 
fermented soymilk (1,000, 2,000 and 3,000 mg/kg b.w.) for 90 d 
(daily). The body weights of rats were measured prior to the study 
and once a week during the study. Measurement of feed intake for all 
rats was conducted weekly during the study. D. grandis fermented 
soymilk was prepared freshly by dissolving D. grandis fermented 
soymilk powder into R. O. water to a concentration of 100 mg/ml, 200 
mg/ml and 300 mg/ml, respectively. Clinical observations for all rats 
were conducted every day by recording abnormal clinical signs or 
death. At the end of the experiment, rats were euthanized with CO2 
asphyxiation and blood samples were collected. 
Urinalysis 
One day before scarification, all rats were placed in metabolic cages 
for 16 h in order to collect urine samples. We used compact urine 
analyzer (PU-400, ARKARY Core Laboratory) to analyze specific 
gravity (SG), color, protein, urobilinogen, pH, ketone body, bilirubin, 
glucose, nitrite and occult blood. The sediments of the urine were 
observed for white blood cell (WBC), red blood cell (RBC), epithelial 
cell (EP), crystals and microbes, etc. by microscopic examination. 
Ophthalmology 
Ophthalmology for all rats was conducted prior to the oral 
administration and at the end of the study. External appearance and 
internal structure of the eyes were evaluated with naked eyes and 
ophthalmoscope. 
Hematology and serum biochemistry 
After overnight fasting, all rats were euthanized with CO2 
asphyxiation and blood samples were collected by cardiac puncture. 
Blood samples were stored in EDTA blood collection tubes and 
mixed well. We used automatic blood analyzer (XT-1800, Sysmex) to 
detect hematocrit, hemoglobin, RBC, WBC, platelet count, mean 
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), 
mean corpuscular hemoglobin concentration (MCHC), lymphocyte, 
neutrophil, monocyte, eosinophil and basophil. Anticoagulated blood 
samples were analyzed by Blood Coagulation Analyzer (CA-1500, 
Sysmex) for prothrombin time. The following serum biochemistry 
parameters were analyzed by using automated analyzer (7070 
Autoanalyzer, Hitachi): alkaline phosphatase (ALP), aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), albumin, 
total protein, total bilirubin, creatinine, blood urea nitrogen (BUN), 
glucose, cholesterol, triglyceride, phosphorus, calcium, chloride, 
potassium and sodium. 
Pathology 
Necropsy examination for all rats was conducted at the end of the 
study (day 91). The outer appearance, oral cavity, cranial cavity and 
all tissues and organs in thoracic and abdominal cavity were 
examined visually and recorded. Major organ weights including 
brain, heart, kidney, liver, spleen, adrenal gland, testis or ovary were 
measured after removal of peripheral fat tissue. In addition, relative 
organ weights were calculated according to the formula:  
Relative organ weight (%) = organ weight (g) ÷ body weight (g) ×
100 Histopathological test was performed for control group and 
high dose group to examine adrenals, aorta, brain, pituitary, spinal 
cord, bone marrow, femur, esophagus, eyes, Harderian gland, heart, 
duodenum, jejunum, ileum, caecum, colon, rectum, kidney, liver, 
lung, lymph node, thyroid/parathyroid gland, salivary gland, spleen, 
pancreas, sciatic nerve, optic nerve, stomach, thigh muscle, thymus, 
urinary bladder, skin, trachea, epididymis, prostate gland, seminal 
vesicle and testis (male), oviduct, uterus, vagina, ovary and 
mammary gland (female). The collected organs were fixed in 10% 
neutral formalin buffer. Preserved organs and tissues were 
dehydrated, clarified, infiltrated with paraffin and embedded after 
trimming, forming paraffin tissue blocks, and cut into 2 μm thickness 
of a tissue slice using paraffin tissue slicing machine (RM 2145, 
Leica), stained with Hematoxylin & Eosin (H&E). The 
histopathological changes were evaluated using an optical 
microscope (BX51, Olympus). If treatment-related changes occurred 
in a particular organ or tissue in the high dose group, extended 
examination for the organ or tissue of medium dose and low dose 
group was included. 
Statistical analysis 
Values are expressed as mean±standard deviation (SD) and analyzed 
using one-way analysis of variance (ANOVA) followed by Duncan’s 
multiple range for comparisons of group means. All statistical 
analyses were performed using SPSS; a P value<0.05 is considered 
statistically significant. 
RESULTS 
Body weight and feed intake 
All animals survived during the study except one female rat in 
the high dose group died on day 75 because of gavage error 
(table 1). No abnormal clinical sign was shown after oral 
administration of R. O. water and D. grandis fermented soymilk. 
The body weight of rats receiving D. grandis fermented soymilk 
was similar to that of the control groups and was not statistically 
significant (fig. 1). Lower feed intake of male rats in medium and 
high dose group of week 11 was observed (p<0.05), but there is 
no significant difference in feed intake of female rats between 
treatment and control group (fig. 2). 
  









Mortality of the rats 
Sex M F M F M F M F 
Number of rat in each group  10 10 10 10 10 10 10 10 
Number of rat died during the study 0 0 0 0 0 0 0 1* 
Incidence of abnormal clinical sign 
Sex M F M F M F M F 
Number of rat in each group  10 10 10 10 10 10 10 9 
Number of rat exhibited abnormal clinical sign 0 0 0 0 0 0 0 0 
M: male; F: female, *Female rat (Animal I.D.: 140400001-39F) was found dead on day 75 caused by technical gavage error. 
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Fig. 1: Effects of D. grandis fermented soymilk on body weight in 
male and female SD rats during the 90-d safety assessment 
aData expressed as mean±SD, n=10 [feed intake of high-dose group 
after week 11, n=9. Female rat (Animal I.D.: 140400001-39F) was 
found dead on day 75 caused by technical gavage error.]. 
Error bars have been omitted for the simple presentation. 
 
Urinalysis 
There was no significant difference in the examination of urine 
sediments and routine test of the urinalysis between treatment and 
control groups of both sexes (table 2). 
Ophthalmology 
Results revealed that no abnormal findings were observed in 
ophthalmological examination by naked eyes and 
ophthalmoscopic diagnosis for treated and control groups of both sexes 
prior to the oral administration and at the end of the study (table 3). 
 
 
Fig. 2: Effects of D. grandis fermented soymilk on feed intake in 
male and female SD rats during the 90-d safety assessment 
aData expressed as mean±SD, n=5 (2 rats in one cage). 
*Significant different from control group (p<0.05). 
Error bars have been omitted for the simple presentation. 
 
Table 2: Urinalysis of rats after 90 d of Deinococcus grandis fermented soymilk administration 
Items Dosage (mg/kg b.w.) 
Male Female 
0 1000 2000 3000 0 1000 2000 3000 
Color Yellow 9/10 6/10 8/10 6/10 0/10 0/10 0/10 3/9 
Pale yellow 1/10 4/10 2/10 4/10 10/10 10/10 10/10 6/9 
Clarity Clear 0/10 1/10 1/10 0/10 1/10 0/10 1/10 1/9 
Light turbid 10/10 9/10 9/10 10/10 9/10 10/10 9/10 8/9 
Glucose Negative 10/10 10/10 10/10 10/10 10/10 10/10 10/10 9/9 
Trace 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/9 
Bilirubin Negative 10/10 10/10 10/10 10/10 10/10 10/10 10/10 9/9 
1+ 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/9 
Ketone Negative 7/10 9/10 6/10 6/10 10/10 10/10 10/10 8/9 
Trace 3/10 1/10 4/10 4/10 0/10 0/10 0/10 1/9 
1+ 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/9 
Specific gravity <1.015 2/10 3/10 1/10 4/10 10/10 8/10 7/10 3/9 
1.016 ~ 1.020 6/10 5/10 6/10 2/10 0/10 1/10 3/10 3/9 
1.021 ~ 1.025 1/10 0/10 2/10 4/10 0/10 1/10 0/10 2/9 
1.026 ~ 1.030 1/10 2/10 1/10 0/10 0/10 0/10 0/10 1/9 
>1.030 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/9 
pH 5.5 0/10 0/10 0/10 0/10 1/10 3/10 2/10 0/9 
6.0 0/10 1/10 1/10 0/10 3/10 2/10 6/10 4/9 
6.5 7/10 6/10 5/10 4/10 6/10 4/10 2/10 5/9 
7.0 3/10 3/10 4/10 6/10 0/10 1/10 0/10 0/9 
Protein Negative 0/10 0/10 0/10 0/10 8/10 9/10 8/10 2/9 
Trace 0/10 1/10 1/10 2/10 2/10 0/10 2/10 5/9 
1+ 8/10 4/10 7/10 7/10 0/10 1/10 0/10 2/9 
2+ 2/10 5/10 2/10 1/10 0/10 0/10 0/10 0/9 
Urobilinogen Normal 9/10 8/10 9/10 10/10 10/10 10/10 10/10 8/9 
1+ 1/10 2/10 1/10 0/10 0/10 0/10 0/10 1/9 
Nitrite Negative 8/10 9/10 9/10 8/10 7/10 9/10 10/10 8/9 
1+ 1/10 0/10 1/10 2/10 3/10 1/10 0/10 1/9 
2+ 1/10 1/10 0/10 0/10 0/10 0/10 0/10 0/9 
Occult Blood Negative 3/10 1/10 5/10 6/10 10/10 10/10 10/10 8/9 
Trace 4/10 5/10 3/10 3/10 0/10 0/10 0/10 1/9 
1+ 3/10 3/10 1/10 0/10 0/10 0/10 0/10 0/9 
3+ 0/10 1/10 1/10 1/10 0/10 0/10 0/10 0/9 
Leukocyte esterase 
(Leu/µl) 
Negative 2/10 3/10 1/10 1/10 10/10 9/10 10/10 6/9 
25 1/10 1/10 0/10 0/10 0/10 1/10 0/10 2/9 
75 1/10 0/10 3/10 3/10 0/10 0/10 0/10 1/9 
250 2/10 2/10 2/10 4/10 0/10 0/10 0/10 0/9 
500 4/10 4/10 4/10 2/10 0/10 0/10 0/10 0/9 
n/n: Affected rats/total examined rats (n=10 [high dose group of female rats, n = 9. Female rat (Animal I.D.: 140400001-39F) was found dead on day 
75 caused by technical gavage error]). 
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before the study 
Sex M F M F M F M F 
Number of rat in each group  10 10 10 10 10 10 10 10 
Number of rat exhibited ophthalmic abnormality 0 0 0 0 0 0 0 0 
at the end of the study 
Sex M F M F M F M F 
Number of rat in each group  10 10 10 10 10 10 10 9 
Number of rat exhibited ophthalmic abnormality 0 0 0 0 0 0 0 0 
M: male; F: female. 
 
Hematology 
In male rats, there is no significant difference in hematological analysis 
between treatment and control groups except that prothrombin time 
of three treatment groups was significantly lower than the control 
group (p<0.05). On the other hand, there is no significant in the 
hematological analysis for female rates between treatment and control 
groups except that platelet of medium dose group was significantly 
lower than the control group (p<0.05) (table 4, 6). 
Serum biochemistry 
Three serum biochemistry parameters in male rats were noted to be 
statistically significant. In male rats, AST of low dose and high dose 
group, total protein of the high dose group and albumin of three 
treatment groups was significantly lower than the control group 
(p<0.05). No significant difference was observed in serum 
biochemistry parameters for female rats (table 5). 
 











WBC (103/µl) 14.1±3.5 12.6±1.8 11.7±3.3 11.8±4.0 
RBC (106/µl) 9.64±0.68 9.42±0.69 9.19±0.51 9.47±0.43 
Hemoglobin (g/dl) 16.4±0.8 16.3±1.1 16.4±0.6 16.4±0.8 
Hematocrit (%) 48.2±2.7 47.6±3.0 48.0±2.7 47.4±3.2 
MCV (fL) 50.2±4.4 50.7±3.3 52.6±5.7 50.1±3.7 
MCH (pg) 17.1±1.0 17.3±0.7 17.9±1.4 17.3±0.9 
MCHC (g/dl) 34.1±1.1 34.3±1.0 34.2±0.8 34.6±1.0 
Platelet (103/µl) 1059.2±172.2 1009.6±83.8 950.7±170.5 1018.1±124.8 
Neutrophil (%) 19.5±8.8 17.0±3.7 20.3±8.0 20.6±8.8 
Lymphocyte (%) 73.2±8.8 75.5±3.5 72.3±8.9 72.2±9.2 
Monocyte (%) 6.0±0.9 6.1±1.1 6.0±1.3 5.8±1.5 
Eosinophil (%) 1.2±0.6 1.3±0.5 1.3±0.4 1.3±0.7 
Basophil (%) 0.2±0.1 0.2±0.1 0.2±0.1 0.2±0.1 
Reticulocyte (%) 3.1±2.2 2.2±0.9 2.4±0.8 2.0±0.8 
PT (sec.) 17.9±1.8 11.3±0.3* 11.1±0.3* 12.8±4.9* 
Female 
WBC (103/µl) 8.7±2.5 10.8±2.8 9.1±2.0 8.0±1.2 
RBC (106/µl) 9.01±0.56 9.02±0.41 8.72±0.57 8.73±0.37 
Hemoglobin (g/dl) 16.3±0.8 16.3±0.6 15.8±0.9 16.0±0.5 
Hematocrit (%) 47.8±1.6 47.5±1.9 46.6±2.3 46.9±2.0 
MCV (fL) 53.3±3.0 52.7±1.6 53.5±2.1 53.8±2.2 
MCH (pg) 18.1±0.8 18.1±0.4 18.2±0.5 18.4±0.6 
MCHC (g/dl) 34.0±0.8 34.4±0.6 34.0±0.9 34.2±0.5 
Platelet (103/µl) 964.3±95.1 958.2±85.4 855.5±117.4* 983.4±87.8 
Neutrophil (%) 15.2±4.9 12.8±4.7 14.1±4.5 18.3±4.4 
Lymphocyte (%) 77.6±6.2 81.6±5.4 79.4±5.6 74.5±5.2 
Monocyte (%) 5.5±1.4 4.3±1.4 5.0±1.4 5.6±1.8 
Eosinophil (%) 1.5±0.6 1.1±0.9 1.3±0.4 1.4±0.4 
Basophil (%) 0.2±0.1 0.2±0.0 0.2±0.1 0.2±0.1 
Reticulocyte (%) 2.9±2.6 2.7±0.4 2.0±0.5 2.4±0.7 
PT (sec.) 10.1±0.3 10.0±0.2 10.1±0.3 10.1±0.4 
aData expressed as mean±SD, n=10 [high dose group of female rats, n = 9. Female rat (Animal I.D.: 140400001-39F) was found dead on day 75 
caused by technical gavage error]. 
WBC, white blood cell count; RBC, red blood cell count; MCV, mean corpuscular volume; MCH, mean cell hemoglobin; MCHC, mean corpuscular 
hemoglobin concentration; PT, prothrombin time., *Significant different from control group (p<0.05). 
Normal range of Prothrombin time: 10.3 ~ 18.2 sec [22]., Normal range of Platelet: 561 ~ 1377 x 103/µl [22]. 
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Table 5: Clinical chemistry of rats after 90 d of Deinococcus grandis fermented soymilk administration 










Glucose (mg/dL) 215.4±19.3 214.0±46.0 194.7±25.0 198.1±33.9 
BUN (mg/dL) 15.4±2.3 15.1±2.2 16.5±1.5 15.4±1.3 
Creatinine (mg/dL) 0.73±0.05 0.68±0.04 0.70±0.05 0.68±0.04 
AST (U/l) 125.7±36.9 93.0±17.5* 114.6±16.5 96.1±16.1* 
ALT (U/l) 44.2±14.2 36.6±8.3 40.7±11.0 34.9±7.7 
Total protein (g/dL) 6.9±0.3 6.8±0.2 6.7±0.2 6.6±0.2* 
Albumin (g/dL) 4.5±0.1 4.3±0.2* 4.4±0.2* 4.4±0.1* 
ALP (U/l) 76.1±13.6 65.2±10.6 70.9±15.4 77.7±16.8 
Cholesterol (mg/dL) 67.0±15.8 62.0±17.1 65.4±17.4 65.3±17.6 
Triglyceride (mg/dL) 78.7±20.9 71.3±31.4 67.9±21.5 74.2±30.7 
Calcium (mg/dL) 11.5±0.3 11.5±0.3 11.3±0.4 11.3±0.3 
Phosphorus (mg/dL) 8.8±0.5 8.8±0.5 8.6±0.7 8.7±0.8 
Sodium (meq/l) 149.5±1.4 148.9±1.6 148.7±1.7 149.3±1.6 
Potassium (meq/l) 5.9±0.5 5.7±0.5 6.2±0.8 5.7±0.8 
Chloride (meq/l) 103.9±2.4 104.5±1.0 103.9±1.9 103.4±0.5 
Globulin (g/l) 2.3±0.2 2.4±0.2 2.3±0.2 2.2±0.2 
Total bilirubin (mg/dL) 0.007±0.003 0.009±0.004 0.007±0.001 0.008±0.002 
Female 
Glucose (mg/dL) 138.6±29.4 152.7±29.0 169.3±46.0 161.9±22.4 
BUN (mg/dL) 15.5±2.2 15.3±2.9 16.4±2.6 15.3±2.3 
Creatinine (mg/dL) 0.74±0.08 0.73±0.05 0.76±0.07 0.76±0.07 
AST (U/l) 102.6±25.9 84.4±13.8 113.8±45.9 85.9±17.6 
ALT (U/l) 36.5±16.2 26.6±5.8 40.3±20.8 27.4±6.5 
Total protein (g/dL) 7.0±0.4 7.1±0.3 7.2±0.5 7.0±0.6 
Albumin (g/dL) 5.1±0.3 5.2±0.3 5.3±0.3 5.1±0.4 
ALP (U/l) 32.5±7.8 35.7±14.7 29.6±7.2 33.9±5.9 
Cholesterol (mg/dL) 90.9±21.6 83.5±12.6 90.4±20.4 81.2±15.3 
Triglyceride (mg/dL) 60.8±31.7 57.8±69.0 57.1±35.1 34.0±10.0 
Calcium (mg/dL) 11.0±0.6 11.3±0.5 11.3±0.4 10.7±0.5 
Phosphorus (mg/dL) 8.1±0.8 8.4±1.0 8.3±1.2 8.0±0.9 
Sodium (meq/l) 138.8±4.3 142.0±4.7 142.6±3.7 139.3±4.2 
Potassium (meq/l) 6.4±1.0 6.3±0.5 6.4±0.8 6.1±1.1 
Chloride (meq/l) 97.9±4.3 100.8±3.4 99.9±3.4 97.6±2.9 
Globulin (g/l) 1.9±0.3 2.0±0.2 1.9±0.3 1.8±0.3 
Total bilirubin (mg/dL) 0.011±0.004 0.012±0.002 0.013±0.004 0.011±0.003 
aData expressed as mean±SD, n=10 [high dose group, n = 9. Female rat (Animal I.D.: 140400001-39F) was found dead on day 75 caused by technical 
gavage error.]. 
BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase, *Significant different from 
control group (p<0.05), Normal range of AST: 56.1 ~ 201.8 U/l [22], Normal range of Total protein: 6.5 ~ 8.1 g/dL [22], Normal range of Albumin: 
2.9 ~ 4.1 g/dL [22] 
 
Table 6: Microscopic examination of urinary sediments of rats after 90 d of Deinococcus grandis fermented soymilk administration 
Items Dosage (mg/kg BW) 
Male Female 
0 1000 2000 3000 0 1000 2000 3000 
Cell type RBC 0-1 (hpf) 10/10 10/10 10/10 10/10 10/10 10/10 9/10 9/9 
2-5 (hpf) 0/10 0/10 0/10 0/10 0/10 0/10 1/10 0/9 
WBC 0-1 (hpf) 9/10 9/10 10/10 10/10 10/10 10/10 10/10 9/9 
2-5 (hpf) 0/10 1/10 0/10 0/10 0/10 0/10 0/10 0/9 
6-15 (hpf) 1/10 0/10 0/10 0/10 0/10 0/10 0/10 0/9 
EP 0-1 (hpf) 9/10 5/10 6/10 9/10 8/10 8/10 8/10 8/9 
2-5 (hpf) 0/10 3/10 4/10 1/10 2/10 2/10 1/10 0/9 
6-15 (hpf) 1/10 2/10 0/10 0/10 0/10 0/10 1/10 1/9 
Crystal None found 3/10 7/10 5/10 6/10 9/10 10/10 8/10 5/9 
Triple phosphates 7/10 3/10 5/10 4/10 0/10 0/10 0/10 3/9 
Calcium oxalate 0/10 0/10 0/10 0/10 1/10 0/10 2/10 1/9 
n/n: Affected rats/total examined rats (n=10 [high dose group of female rats, n = 9. Female rat (Animal I.D.: 140400001-39F) was found dead on day 
75 caused by technical gavage error]). EP: epithelial cells; WBC: white blood cell; RBC: red blood cell; hpf: high power field. 
 
Pathology 
In male rats, there are no significant differences in absolute organ 
weight and relative organ weight between treatment and control 
groups. In female rats, except for the ovaries of the high dose group 
and adrenal gland of the low dose and medium dose group, no 
significant difference in absolute organ weights was observed 
between the treatment and control groups. And except for the liver 
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of medium dose and high dose group was significantly heavier than 
the control group (p<0.05), there was no significant difference 
between treatment and control groups for other organs (table 8, 9). 
No significant treatment-related changes for all rats were observed 
in adrenals, aorta, brain, pituitary, spinal cord, bone marrow, femur, 
esophagus, eyes, Harderian gland, heart, duodenum, jejunum, ileum, 
caecum, colon, rectum, kidney, liver, lung, lymph node, thyroid/ 
parathyroid gland, salivary gland, spleen, pancreas, sciatic nerve, 
optic nerve, stomach, thigh muscle, thymus, urinary bladder, skin, 
trachea, epididymis, prostate gland, seminal vesicle and testis 
(male), oviduct, uterus, vagina, ovary and mammary gland (female) 
of the treatment and control group (table 10). 
In male rats, mononuclear cell infiltration was found in Harderian 
gland of control and high dose group (incidence rate of 2/10 and 
1/10), in heart of control and high dose group (incidence rate of 
4/10 and 3/10), in prostate gland of control and high male rats 
(incidence rate of 4/10 and 2/10) and in pancreas of control male 
rats (incidence rate of 3/10); in female rats, mononuclear cell 
infiltration was found in Harderian gland of control group (incidence 
rate of 1/10) and in heart of control group (incidence rate of 1/10).  
 
Table 7: Incidence of gross lesion after 90 d of Deinococcus grandis fermented soymilk administration 









Number of rat in each group  10 10 10 10 
Number of rat exhibited gross lesion 0 0 0 0 
Female 
Number of rat in each group  10 10 10 9 
Number of rat exhibited gross lesion 0 0 0 0 
 
Table 8: Absolute organ weight of rats after 90 d of Deinococcus grandis fermented soymilk administration 
 Absolute organ weight (g)a 
Control 0 mg/kg Low dose 1000 mg/kg Medium dose 2000 mg/kg High dose 3000 mg/kg 
Male 
Testis 3.79±0.38 3.86±0.24 3.69±0.29 3.73±0.31 
Adrenal gland 0.053±0.007 0.059±0.009 0.059±0.010 0.061±0.007 
Spleen 0.957±0.185 0.878±0.098 0.847±0.100 0.885±0.097 
Kidney 3.99±0.53 3.90±0.41 4.01±0.28 4.02±0.42 
Heart 2.02±0.25 1.84±0.16 1.79±0.22 1.84±0.16 
Brain 2.19±0.05 2.19±0.08 2.21±0.07 2.16±0.05 
Liver 16.6±2.3 15.8±1.7 15.6±1.8 15.5±2.0 
Female 
Ovary 0.065±0.008 0.075±0.011 0.069±0.013 0.081±0.016* 
Adrenal gland 0.058±0.007 0.069±0.012* 0.067±0.008* 0.063±0.007 
Spleen 0.508±0.091 0.497±0.070 0.517±0.044 0.540±0.074 
Kidney 1.98±0.15 2.03±0.16 2.13±0.11 2.10±0.11 
Heart 1.01±0.09 1.01±0.05 1.05±0.08 1.04±0.05 
Brain 1.95±0.07 1.95±0.06 1.96±0.05 1.95±0.05 
Liver 7.62±0.61 7.79±0.78 8.46±0.89 8.13±0.50 
aData expressed as mean±SD, n=10 [high dose group of female rats, n = 9. Female rat (Animal I.D.: 140400001-39F) was found dead on day 75 
caused by technical gavage error.]. 
*Significant different from control group (p<0.05). 
 
Table 9: Relative organ weight of rats after 90 d of Deinococcus grandis fermented soymilk administration 
 Relative organ weight (g/100 g B.W.)a 
Control 0 mg/kg Low dose 1000 mg/kg Medium dose 2000 mg/kg High dose 3000 mg/kg 
Male 
Testis 0.676±0.067 0.733±0.099 0.703±0.077 0.714±0.103 
Adrenal gland 0.009±0.001 0.011±0.003 0.011±0.002 0.012±0.002 
Spleen 0.170±0.026 0.165±0.019 0.161±0.015 0.169±0.020 
Kidney 0.711±0.067 0.734±0.061 0.761±0.026 0.763±0.043 
Heart 0.360±0.036 0.346±0.038 0.339±0.034 0.350±0.025 
Brain 0.393±0.041 0.415±0.052 0.421±0.027 0.412±0.034 
Liver 2.95±0.26 2.96±0.20 2.95±0.21 2.94±0.23 
Female 
Ovary 0.024±0.004 0.027±0.004 0.025±0.005 0.029±0.006 
Adrenal gland 0.021±0.003 0.025±0.004 0.025±0.003 0.023±0.002 
Spleen 0.185±0.031 0.181±0.028 0.187±0.016 0.197±0.028 
Kidney 0.722±0.045 0.738±0.064 0.769±0.065 0.766±0.047 
Heart 0.370±0.039 0.365±0.020 0.380±0.031 0.379±0.017 
Brain 0.712±0.040 0.710±0.042 0.711±0.074 0.711±0.041 
Liver 2.77±0.13 2.83±0.18 3.05±0.20* 2.97±0.18* 
aData expressed as mean±SD, n=10 [high dose group of female rats, n = 9. Female rat (Animal I.D.: 140400001-39F) was found dead on day 75 
caused by technical gavage error.]. 
*Significant different from control group (p<0.05). 
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In kidney, one male rat in the control group exhibited focal, slight, 
hyaline cast accumulation and one female rat of the high-dose group 
exhibited focal, slight, cortex infarction. Only one female rat in the 
control group presented focal, slight, necrosis in the liver. 
Alveolar aggregation was observed in the lung of control and high 
dose female rats (incidence rate of 1/10 and 1/9). There was one 
male rat in the control group exhibited focal, slight, ductal 
hyperplasia in the pancreas. Only one male rat in the control group 
exhibited focal, slight, acinar cell regeneration in the pancreas. Focal, 
minimal to slight, cyst was found in the pituitary gland of control 
and high dose male rats (incidence rate of 1/10 and 1/10). 
According to the results, the incidence of histopathological change 
was not directly correlated to the treatment of the test article. 
 
Table 10: Histopathological examination of rats after 90 d of Deinococcus grandis fermented soymilk administration 
Organ Lesions Group 
Control High dose 
Male Female Male Female 
Adrenal gland - - - - 
Aorta - - - - 
Brain 
Fore  - - - - 
Middle  - - - - 
Cerebellum  - - - - 
Stem  - - - - 
Bone, femur  - - - - 
Bone marrow, 
Femur 
 - - - - 
Sternum  - - - - 
Epididymis  - N - N 
Esophagus  - - - - 
Eyes  - - - - 
Harderiangland 
 Infiltration, mononuclear cell, focal, minimal to moderate 2/10 2/10 1/10 - 
Heart 
 Infiltration, mononuclear cell, focal, minimal to slight 4/10 1/10 3/10 - 
-: no effect. N: tissue was not available 
1Degree of lesion was graded from one to five depending on severity: minimal (<1%); slight (1-25%); moderate (26-50%); moderate/severe (51-
75%); severe/high (76-100%). 
2Incidence: Affected rats/Total examined rats (n=10). 
 
Table 10: Histopathological examination of rats after 90 d of Deinococcus grandis fermented soymilk administration (continue) 
Organ Lesions Group 
Control High dose 
Male Female Male Female 
Intestine, small 
Doudenum  - - - - 
Jejunum  - - - - 
Ileum  - - - - 
Intestine, large 
Caecum  - - - - 
Colon  - - - - 
Rectum  - - - - 
Kidney 
 Cast, tubule, focal, slight 1/10 - - - 
 Infact, cortex, focal, slight - - - 1/9 
Liver 
 Necrosis, hepatocyte, focal, slight - 1/10 - - 
Lung 
 Aggregation, macrophage, focal, minimal - 1/10 - 1/9 
Lymph node, 
Cervical  - - - - 
Mesenteric  - - - - 
Mammary gland  N - N - 
Optic nerve  - - - - 
-: no effect. N: tissue was not available 
1Degree of lesion was graded from one to five depending on severity: minimal (<1%); slight (1-25%); moderate (26-50%); moderate/severe (51-
75%); severe/high (76-100%). 
2Incidence: Affected rats/Total examined rats (n=10). 
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Table 10: Histopathological examination of rats after 90 d of Deinococcus grandis fermented soymilk administration (continue) 
Organ Lesions Group 
Control High dose 
Male Female Male Female 
Ovary  N - N - 
Oviduct  N - N - 
Pancreas 
 Hyperplasia, ductal, focal, slight 1/10 - - - 
 Infiltration, mononuclear cell, focal, minimal to slight 3/10 - - - 
 Regeneration, acinar, focal, slight 1/10 - - - 
Pituitary 
 Cyst, pars distails, focal, minimal to slight 1/10 - 1/10 - 
Parathyroid gland  - - - - 
Prostate gland 
 Infiltration, mononuclear cell, focal, minimal to slight 4/10 N 2/10 N 
Salivary gland 
Mandibular lobe  - - - - 
Sublingual lobe  - - - - 
Sciatic nerve  - - - - 
Seminal vesicle  - N - N 
Skeletal muscle  - - - - 
Skin  - - - - 
-: no effect. N: tissue was not available 
1Degree of lesion was graded from one to five depending on severity: minimal (<1%); slight (1-25%); moderate (26-50%); moderate/severe (51-
75%); severe/high (76-100%). 
2Incidence: Affected rats/Total examined rats (n=10). 
 
Table 10: Histopathological examination of rats after 90 d of Deinococcus grandis fermented soymilk administration (continue) 
Organ Lesions Group 
Control High dose 
Male Female Male Female 
Spinal code 
Cervical  - - - - 
Lumbar  - - - - 
Thoracic  - - - - 
Spleen  - - - - 
Stomach  - - - - 
Testes  - N - N 
Thymus  - - - - 
Thyroid gland  - - - - 
Tongue  - - - - 
Trachea  - - - - 
Urinary bladder  - - - - 
Uterus  N - N - 
Vagina  N - N - 
-: no effect. N: tissue was not available 
1Degree of lesion was graded from one to five depending on severity: minimal (<1%); slight (1-25%); moderate (26-50%); moderate/severe (51-
75%); severe/high (76-100%). 
2Incidence: Affected rats/Total examined rats (n=10). 
 
DISCUSSION 
During the study period, no abnormality occurred in clinical signs, 
body weight, and ophthalmological examination. In male rats, body 
weights and feed intake were reduced dose-dependently but not 
significantly. The finding suggests that oral administration of D. 
grandis fermented soymilk slightly affects food intake in male rats, 
leading to decreased body weights. 
There were no significant differences in urinalysis between the 
treatment and control group. A few parameters in hematology and 
clinical biochemistry analysis showed significant differences 
between the treatment and control group, including prothrombin 
time, AST, total protein and albumin in male rats, and platelet in 
female rats. The prothrombin time, AST, total protein in male rats 
and platelet in female rats were all within the normal range. 
Albumin in male rats was all higher than normal level but still close 
to the normal range. Previous studies have shown that menaquinone 
(MK-8) was found in the respiratory chain of D. grandis [20] and 
abnormal prothrombin can be eliminated or lowered by 
administration of vitamin K [21]. Therefore, lowered PT may be 
caused by oral administration of D. grandis fermented soymilk which 
contains MK-8. These results suggest that no toxicity effect was 
induced by oral administration of D. grandis fermented soymilk.  
Necropsy and histopathological examination found no treatment-
related change. Although absolute organ weights of ovary of high 
dose group and adrenal gland of low and medium dose group in 
female rats were significantly higher than the control group, there 
was no significant difference between the relative weight of these 
organs in high dose group and control group (p>0.05). In female 
rats, relative weights of liver of medium and high dose group were 
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significantly heavier than control group (p<0.05), but serum AST, 
ALT and histopathological examination of liver showed no 
significant difference between high dose group and control group, 
indicating that these were primarily related to individual variations 
and not a toxic effect induced by D. grandis fermented soymilk. Non-
specific histopathological changes were observed including focal 
mononuclear cell infiltration in Harderian gland, heart and prostate 
gland of male rats; focal hyaline cast and focal cortex infarction in 
kidney; focal necrosis in liver; focal alveolar aggregation in lung; 
focal ductal hyperplasia, mononuclear cell infiltration and acinar cell 
regeneration in pancreas and focal cyst in pituitary gland. There was 
no positive correlation between incidence rate and oral 
administration of D. grandis fermented soymilk. These 
histopathological changes were non-specific, and not induced by 
oral administration of D. grandis fermented soymilk. 
CONCLUSION 
The present study demonstrates that the 90-day subchronic 
toxicological assessment showed no systemic toxicity attributable to 
D. grandis fermented soymilk administration, and no significant 
toxicity occurred even at the highest dose of 3,000 mg/kg b.w./d in 
SD rats. Results from the 90-day subchronic toxicity study of D. 
grandis fermented soymilk do not raise concern with respect to 
possible use as a functional food ingredient. According to the results, 
the no-observed-adverse-effect level (NOAEL) of D. grandis 
fermented soymilk was greater than 3,000 mg/kg b.w./d in SD rats. 
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